Strontium ion (Sr2+) (Sr2+)

Strontium ions (Sr2+) are divalent alkaline earth metal cations that exhibit a high affinity for bone tissue due to their chemical similarity to calcium (Source: PubChem). They function as a dual-action bone agent by simultaneously promoting bone formation and reducing bone resorption (Source: StatPearls). This is primarily mediated through the activation of the Calcium-sensing receptor (CaSR) on osteoblasts and the modulation of the RANKL/osteoprotegerin (OPG) ratio, which leads to increased osteoblast activity and induced osteoclast apoptosis (Source: PMC2672150). Clinically, strontium compounds such as strontium ranelate have been employed to treat postmenopausal osteoporosis by increasing bone mineral density and reducing fracture risk. Additionally, the radioisotope strontium-89 is used as a radiopharmaceutical for the palliative treatment of painful bone metastases in cancers such as prostate and breast cancer (Source: NIH). However, the use of strontium is associated with significant safety considerations, including an increased risk of cardiovascular events and the potential for DRESS syndrome (Source: EMA). Furthermore, strontium incorporation into bone can lead to an overestimation of bone mineral density during dual-energy X-ray absorptiometry (DXA) scans, requiring correction factors for accurate assessment.

Other names

Strontium(2+)Strontium cationSr(II)Strontium

Strontium ions act as agonists of the Calcium-sensing receptor (CaSR), stimulating the differentiation of pre-osteoblasts to osteoblasts and increasing collagen synthesis. Simultaneously, they inhibit osteoclast differentiation and promote osteoclast apoptosis, leading to a net increase in bone formation over resorption. They also physically incorporate into the bone matrix (Source: PMC2672150, StatPearls).